Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06482268 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06482268 · ClinicalTrials.gov record · last posted 2026-08-17

Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)

Study acronym: CT1-DAP001
StatusRecruiting
PhasePhase 1
Started2024-06-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease

Protocol amendment history 2 changes detected by DataLookout

2026-08-18
Primary endpoint(s) modified
WasACCEPTABILITY, SAFETY
NowACCEPTABILITY, Incidence And Severity Of Adverse Events
2026-08-18
Primary completion pushed: 2025-02-28 → 2027-12-28
Trial Details
NCT Number NCT06482268
Lead Sponsor University of California, San Diego
Collaborators: Sumitomo Pharma America, Inc., Kyoto University, Sumitomo Pharma Co., Ltd.
Conditions PD - Parkinson's Disease
Enrollment 7 participants
Start Date 2024-06-01
Primary Completion 2027-12-28 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-17